Distinct fibroblast subsets drive inflammation and damage in arthritis, 2019

Topics: Synovial fibroblasts; inflammation; arthritis; transcriptomics; rheumatoid arthritis

Authors: Adam P Croft, Joana Campos, Kathrin Jansen, Jason D Turner, Jennifer Marshall,
Moustafa Attar, Loriane Savary, Corinna Wehmeyer, Amy J. Naylor, Samuel Kemble,
Jenefa Begum, Kerstin Duerholz, Harris Perlman, Francesca Barone, Helen M
McGettrick, Douglas T Fearon, Kevin Wei, Soumya Raychaudhuri, Ilya Korsunsky,
Michael B Brenner, Mark Coles, Stephen N Sansom, Andrew Filer, Christopher D
Buckley

Abstract

The identification of lymphocyte subsets with non-overlapping effector functions has been pivotal to the development of targeted therapies in immune-mediated inflammatory diseases (IMIDs)1,2. However, it remains unclear whether fibroblast subclasses with non-overlapping functions also exist and are responsible for the wide variety of tissue-driven processes observed in IMIDs, such as inflammation and damage3-5. Here we identify and describe the biology of distinct subsets of fibroblasts responsible for mediating either inflammation or tissue damage in arthritis. We show that deletion of fibroblast activation protein-α (FAPα)+ fibroblasts suppressed both inflammation and bone erosions in mouse models of resolving and persistent arthritis. Single-cell transcriptional analysis identified two distinct fibroblast subsets within the FAPα+ population: FAPα+THY1+ immune effector fibroblasts located in the synovial sub-lining, and FAPα+THY1- destructive fibroblasts restricted to the synovial lining layer. When adoptively transferred into the joint, FAPα+THY1- fibroblasts selectively mediate bone and cartilage damage with little effect on inflammation, whereas transfer of FAPα+ THY1+ fibroblasts resulted in a more severe and persistent inflammatory arthritis, with minimal effect on bone and cartilage. Our findings describing anatomically discrete, functionally distinct fibroblast subsets with non-overlapping functions have important implications for cell-based therapies aimed at modulating inflammation and tissue damage.

Related research articles